Sign in
CompletedNo phase

A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder

Key facts

Who runs it
The University of Texas Health Science Center, Houston
Where
Houston, United StatesSee the site
Trial code
Status
Completed
People taking part
14 people enrolled
Started
31 Mar 2025
Ended
15 Sept 2026
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • EFT
  • high frequency rTMS
  • sham frequency rTMS
Record updated
24 September 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for primary methamphetamine use disorder
  • Be fluent in English and able to understand the consent form

Who cannot take part

  • Medical implants contraindicating TMS (i.e., aneurysm clips or coils, stents, implanted stimulators, implanted vagus nerve or deep brain stimulators, implanted electrical devices such as pacemakers or medication pumps, electrodes for monitoring brain activity, cochlear implants for hearing, any magnetic implants, bullet fragments, any other metal device or object implanted in your body closer than 30 cm from the coil)
  • Current DSM-5 diagnosis for any illicit substance use disorder other than methamphetamine and marijuana
  • Current DSM-5 diagnosis of moderate or greater severity for alcohol and marijuana use disorder
  • In the opinion of the PI, the presence of any medical, neurological, psychiatric (e.g., psychotic or bipolar disorder), or physical condition, disease, or illness that, may: (a) compromise, interfere, limit, effect or reduce the subject's ability to complete the study; or (b) adversely impact the safety of the subject or the integrity of the data
  • History of brain surgery
  • History of an intracranial lesion or any medical or neurological diagnosis/condition associated with increased intracranial pressure (i.e., Idiopathic Intracranial Hypertension/Pseudotumor Cerebri) OR any of the following symptoms within 30 days of enrollment: headaches > 15 days/month, loss of vision or decreased vision
  • Moderate-to-severe heart disease
  • History of stroke
  • Is taking any antidepressant or antipsychotic medication at a dose above the maximum recommended dose or at a dose deemed to be potentially unsafe according to the PI; has taken any of the following medications, which are known to increase the risk of seizures, within 1 week of study enrollment; or does not agree to abstain from taking the following medications during study participation:; clozapine; chlorpromazine; bupropion; clomipramine hydrochloride; amoxapine; maprotiline hydrochloride; diphenhydramine; stimulants other than methamphetamine including the following: Dextroamphetamine and amphetamine, Dextroamphetamine, Lisdexamfetamine dimesylate, Cocaine, Methylphenidate,; tramadol; isoniazid
  • Personal history of epilepsy or seizure disorder and/or family history including a first-degree relative
  • For adolescent aged participants (18-21 only): any risk factor for neurocardiogenic syncope (history of syncope/presyncope related to noxious stimuli, anxiety, micturition, or posture)
  • Has current or recent (within 3 months of potential enrollment) suicidal ideation, suicidal behavior, homicidal ideation or a homicidal plan sufficient to raise subject safety concerns based on the following assessments according to the PI:; Structured Clinical Interview for DSM-5 (SCID-5); Columbia-Suicide Severity Rating Scale (C-SSRS) Screening - Answers YES to Questions 3, 4, 5, or 6; Assault \& homicidal danger assessment tool - Key to danger >1
  • Serious head injury with loss of consciousness
  • Impending incarceration
  • Pregnant or nursing females
  • Inability to read, write, or speak English

Where in United States

  • The University of Texas Health Science Center at HoustonHouston, United States

About the trial

What the trial wants to find out

The purpose of this study is to assess impact of repetitive transcranial magnetic stimulation (rTMS)+Episodic Future Thinking (EFT) vs. sham rTMS+EFT on delay discounting and methamphetamine (MA) demand, on vividness of future positive events during EFT training and on frequency of episodic thinking during the week following EFT training

The 2 groups in the trial

  • highfrequency rTMS+EFTTreatment being tested

    Treatment: EFT and high frequency rTMS

  • sham rTMS+EFTSham treatment, for comparison

    Treatment: EFT and sham frequency rTMS

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
24 September 2026